Skip to main content
TNYA
NASDAQ Life Sciences

Tenaya Therapeutics Stockholders Approve Expanded Equity Incentive Plan, Increasing Potential Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.882
Mkt Cap
$188.572M
52W Low
$0.431
52W High
$2.35
52W Position info
105% above low
Off High info
62% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TNYA has more than doubled off its 52-week low of $0.431.

Summary

Tenaya Therapeutics stockholders approved an amended equity incentive plan, immediately increasing shares available for issuance by 3% and removing the annual cap on future share reserve increases, signaling significant potential dilution.


Key Events · Financing and Capital Events · TNYA

  • Equity Incentive Plan Approved

    Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, finalizing a proposal previously disclosed on April 16, 2026.

  • Immediate Share Increase

    The plan includes a one-time increase of 6,509,966 shares, representing approximately 3% of the company's outstanding shares, reserved for future issuance.

  • Evergreen Provision Modified

    The annual "evergreen" provision for share reserve increases will now maintain a 4% of outstanding shares increase without the previous 4 million share annual limit, allowing for potentially larger future increases.

  • Director Elections and Auditor Ratification

    Stockholders also approved the routine election of three Class II directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026.


Analysis · TNYA · Life Sciences

Stockholders approved an amended equity incentive plan, which includes an immediate 3% increase in shares reserved for issuance (6.5 million shares) and removes the annual 4 million share cap on the "evergreen" provision. This change means future annual increases to the share reserve will be a full 4% of outstanding shares, potentially leading to greater dilution over time compared to the previous capped structure. While common for employee incentives in biotech, this represents a substantial increase in potential share count.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1410 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNYA was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.6M. The 52-week trading range was $0.43 to $2.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNYA - Latest Insights

TNYA
Nov 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.377
Real-time Price: $0.3305 info
Change: -$0.0465 (-12%) info
Market Cap: $72.025M info
TNYA
Nov 04, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.385
Real-time Price: $0.3305 info
Change: -$0.0545 (-14%) info
Market Cap: $72.025M info
TNYA
Oct 13, 2026, 4:42 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.3305 info
Change: -$0.1995 (-38%) info
Market Cap: $72.025M info
TNYA
Sep 14, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.6395
Real-time Price: $0.3305 info
Change: -$0.309 (-48%) info
Market Cap: $72.025M info
TNYA
Aug 05, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.7497
Real-time Price: $0.3305 info
Change: -$0.4192 (-56%) info
Market Cap: $72.025M info